EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)

No overshoot of bone turnover after withdrawal of denosumab treatment of adults with Langerhans cell histiocytosis: a prospective clinical trial

Polyzois Makras, Maria P Yavropoulou, Athanasios D Anastasilakis, Athanasios Papatheodorou, Socrates E Papapoulos

Osteoporosis International · 2025

DOI: 10.1007/s00198-025-07538-6 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Osteoporosis International, 2025. Verfasst von Polyzois Makras und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Research, 251 Hellenic Air Force & VA General Hospital, 3 Kanellopoulou Str, Athens, Greece. pmakras@gmail.com. Hauptthemen laut MEDLINE: Denosumab, Histiocytosis, Langerhans-Cell, Bone Remodeling, Bone Density Conservation Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: Amgen Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Denosumab (Dmab) discontinuation in osteoporosis leads to overshoot (rebound) of bone turnover, but its cause remains largely unclear. In a prospective trial, Dmab-treated Langerhans cell histiocytosis (LCH) patients showed no overshoot of bone turnover markers despite high short-term dosing. Findings suggest that total Dmab dose does not drive the overshoot of bone turnover markers. PURPOSE: In patients with osteoporosis, the length of treatment with denosumab (Dmab) is an important risk factor for the overshoot (rebound) of bone turnover markers following its discontinuation. Whether this is due to the higher total Dmab dose given and/or the severity of the disease is unknown. To address this question, long-term follow-up of changes in bone metabolism after stopping Dmab with doses higher than those used in osteoporosis is essential. METHODS: In a prospective, single-arm, open label, phase 2b clinical trial, ten adult patients with Langerhans cell histiocytosis (LCH), eight with bone lesions (four single, four multiple) and two without, were treated with Dmab sc injections 120 mg/2 months for 6 months (total 480 mg) and were followed for 24 months after the last injection. RESULTS: Treatment reduced bone turnover markers to about 10% of pretreatment values, which increased after treatment arrest to a peak that did not exceed pretreatment levels; mean (± SD) peak serum CTX 0.522 ± 0.366 ng/mL and P1NP 72.2 ± 35.9 ng/mL were not significantly different from baseline (p = 0.11 and 0.65, respectively). Moreover, pretreatment and peak serum CTX values were significantly correlated (rs = 0.818, p = 0.007). No vertebral fractures, bone loss, or hypercalcemia were observed. CONCLUSION: Dmab withdrawal in patients with LCH was not followed by an overshoot of bone turnover markers or bone loss despite the administration in 6 months of a total dose equal to that given in osteoporosis for 4 years. Total Dmab dose is, thus, not an important determinant of the bone turnover overshoot after treatment withdrawal.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DenosumabHistiocytosis, Langerhans-CellBone RemodelingBone Density Conservation AgentsOsteoporosisHumansFemaleMaleProspective StudiesMiddle AgedAdultBiomarkersAgedWithholding TreatmentDrug Administration ScheduleBone Density

Stichwörter der Autor:innen

Bone markersDenosumabDiscontinuationLangerhans cell histiocytosisOvershootingRebound

Substanzen

DenosumabBone Density Conservation AgentsBiomarkers

Autor:innen und Institutionen

  • Department of Medical Research, 251 Hellenic Air Force & VA General Hospital, 3 Kanellopoulou Str, Athens, Greece. pmakras@gmail.com.
  • Department of Medical Research, LCH Adult Clinic, 251 Hellenic Air Force & VA General Hospital, 3 Kanellopoulou Str, 11525, Athens, Greece. pmakras@gmail.com.
  • Department of Medical Research, LCH Adult Clinic, 251 Hellenic Air Force & VA General Hospital, 3 Kanellopoulou Str, 11525, Athens, Greece.
  • Εndocrinology Unit, First Department of Propaedeutic and Internal Medicine, National and Kapodistrian University of Athens, Medical School, 11527, Athens, Greece.
  • Department of Endocrinology, 424 General Military Hospital, Thessaloniki, Greece.
  • Department of Medical Research, 251 Hellenic Air Force & VA General Hospital, 3 Kanellopoulou Str, Athens, Greece.

Förderung

  • Amgen Foundation

Zitieren

APA

Makras, P., Yavropoulou, M. P., Anastasilakis, A. D., Papatheodorou, A., & Papapoulos, S. E. (2025). No overshoot of bone turnover after withdrawal of denosumab treatment of adults with Langerhans cell histiocytosis: a prospective clinical trial. Osteoporosis International. https://doi.org/10.1007/s00198-025-07538-6

Vancouver

Makras P, Yavropoulou MP, Anastasilakis AD, Papatheodorou A, Papapoulos SE. No overshoot of bone turnover after withdrawal of denosumab treatment of adults with Langerhans cell histiocytosis: a prospective clinical trial. Osteoporosis International. 2025. doi:10.1007/s00198-025-07538-6

BibTeX
@article{Makras2025,
  author = {Makras, Polyzois and Yavropoulou, Maria P and Anastasilakis, Athanasios D and Papatheodorou, Athanasios and Papapoulos, Socrates E},
  title = {No overshoot of bone turnover after withdrawal of denosumab treatment of adults with Langerhans cell histiocytosis: a prospective clinical trial},
  journal = {Osteoporosis International},
  year = {2025},
  doi = {10.1007/s00198-025-07538-6}
}
Kostenlos starten →